ABVC BIOPHARMA, INC. (ABVC)
↓ Download CSV- Sector Manufacturing
- Incorporated NV
- Fiscal year ends Dec 31
In fiscal 2025, ABVC BIOPHARMA, INC. reported revenue of $296.0K. The company ran a net loss, with a net margin of -2671.8%. It held $21.06M in total assets against $7.76M in total liabilities.
Key ratios (FY2025)
-2416.0%
Operating margin
-2671.8%
Net margin
-71.2%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $296.0K | $0 | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | $763 | $302.0K | $286.4K | $5.1K | $18.7K | $20.1K | $185.3K | — | $32 |
| Gross Profit | — | $508.8K | -$149.6K | $683.4K | $350.7K | $464.3K | $681.6K | -$178.3K | — | -$32 |
| Operating Income | -$7.15M | -$4.71M | -$6.77M | -$15.11M | -$11.71M | -$8.51M | -$3.46M | -$2.78M | -$4.14M | -$11.00M |
| Net Income | -$7.91M | -$4.90M | -$7.79M | -$16.42M | -$12.84M | -$10.59M | -$3.93M | -$6.06M | -$4.24M | -$11.01M |
| EPS (Diluted) | $-0.39 | $-0.42 | $-1.80 | $-5.19 | $-0.51 | $-0.50 | — | $-0.02 | $-0.02 | $-0.06 |
| Total Assets | $21.06M | $7.54M | $7.78M | $9.58M | $13.70M | $11.61M | $6.93M | $5.94M | $2.64M | $177.4K |
| Total Liabilities | $7.76M | $6.82M | $6.53M | $6.34M | $4.83M | $8.94M | $7.05M | $11.28M | $4.40M | $6.56M |
| Shareholders' Equity | $11.11M | $1.23M | $1.55M | $3.10M | $8.84M | $3.44M | -$151.0K | -$5.66M | -$1.76M | -$6.52M |
| Cash & Equivalents | $681.5K | $248.4K | $60.2K | $85.3K | $5.83M | $4.27M | $144.3K | $226.7K | $93.3K | $18.6K |
| Operating Cash Flow | -$2.99M | -$1.81M | -$4.19M | -$7.40M | -$7.60M | -$4.56M | -$3.13M | -$900.5K | -$1.49M | -$3.47M |
| Capital Expenditures | — | — | $21.2K | $119.7K | $17.5K | — | — | — | — | — |
| Shares Outstanding | 25.05M | 13.87M | 7.94M | 3.29M | 24.42M | 24.42M | 19.48M | 11.88M | 213.75M | 210.82M |